Kathrin Jansen
卡特琳·扬森
PhD
Senior Vice President and Head of Vaccine Research & Development疫苗研发高级副总裁兼负责人
👥Biography 个人简介
Led the research and development of Gardasil (HPV vaccine) at Merck before joining Pfizer. At Pfizer, oversaw development of Prevnar 20 and COVID-19 vaccine. A pioneer in translating prophylactic cancer vaccine concepts from lab to blockbuster clinical products with global public health impact.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Gardasil Clinical Development
As VP at Merck, led the scientific program that brought Gardasil from research through clinical trials to FDA approval in 2006, the first vaccine licensed specifically to prevent cancer.
Vaccine Platform Leadership
At Pfizer, expanded cancer-relevant vaccine pipelines and oversaw mRNA vaccine technology development, demonstrating the platform's versatility for cancer immunoprevention applications.
Representative Works 代表性著作
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
New England Journal of Medicine (2007)
Phase 3 FUTURE II trial demonstrating Gardasil's near-complete prevention of high-grade cervical lesions, leading to global regulatory approval.
Human papillomavirus (HPV) quadrivalent vaccine: a review of clinical studies
Vaccine (2009)
Comprehensive review of clinical evidence supporting Gardasil's efficacy and safety profile across diverse populations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Ian Frazer
University of Queensland
Cornelia Trimble
Johns Hopkins University School of Medicine
Philip Castle
National Cancer Institute (NCI), NIH
Joakim Dillner
Karolinska Institutet
关注 卡特琳·扬森 的研究动态
Follow Kathrin Jansen's research updates
留下邮箱，当我们发布与 Kathrin Jansen（Pfizer Inc.）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment